Robert J. Fox Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute Cleveland Clinic Biography Publications Institution JoVE Articles Robert J. Fox has not added a biography. If you are Robert J. Fox and would like to personalize this page please email our Author Liaison for assistance. Publications Demyelinating Lesions and Progressive MS: Location, Location, Location Neurology. Jul, 2019 | Pubmed ID: 31289147 The FLUOX-PMS Trial: Underestimating the Challenge in Progressive Multiple Sclerosis Trials Multiple Sclerosis (Houndmills, Basingstoke, England). Jun, 2019 | Pubmed ID: 31218918 Outcomes of Natalizumab Treatment Within 3 years of Relapsing-remitting Multiple Sclerosis Diagnosis: a Prespecified 2-year Interim Analysis of STRIVE BMC Neurology. Jun, 2019 | Pubmed ID: 31176355 Developing a Crosswalk Between the RAND-12 and the Health Utilities Index for Multiple Sclerosis Multiple Sclerosis (Houndmills, Basingstoke, England). Jun, 2019 | Pubmed ID: 31161917 Measures of General and Abdominal Obesity and Disability Severity in a Large Population of People with Multiple Sclerosis Multiple Sclerosis (Houndmills, Basingstoke, England). May, 2019 | Pubmed ID: 31079537 The Association of Fatigue and Social Participation in Multiple Sclerosis As Assessed Using Two Different Instruments Multiple Sclerosis and Related Disorders. Jun, 2019 | Pubmed ID: 31063935 Effect of Dimethyl Fumarate on Lymphocytes in RRMS: Implications for Clinical Practice Neurology. Apr, 2019 | Pubmed ID: 30918100 A Survey of Risk Tolerance to Multiple Sclerosis Therapies Neurology. Apr, 2019 | Pubmed ID: 30867272 Validation of the SymptoMScreen with Performance-based or Clinician-assessed Outcomes Multiple Sclerosis and Related Disorders. Apr, 2019 | Pubmed ID: 30690340 Pseudobulbar Affect: Prevalence and Association with Symptoms in Multiple Sclerosis Neurology. Clinical Practice. Dec, 2018 | Pubmed ID: 30588376 Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis Drugs. Oct, 2018 | Pubmed ID: 30255442 Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis The New England Journal of Medicine. 08, 2018 | Pubmed ID: 30157388 Cortical Neuronal Densities and Cerebral White Matter Demyelination in Multiple Sclerosis: a Retrospective Study The Lancet. Neurology. 10, 2018 | Pubmed ID: 30143361 Discontinuation and Comparative Effectiveness of Dimethyl Fumarate and Fingolimod in 2 Centers Neurology. Clinical Practice. Aug, 2018 | Pubmed ID: 30140580 Progressive Multifocal Leukoencephalopathy with Extended Natalizumab Dosing Neurology. Clinical Practice. Jun, 2018 | Pubmed ID: 30105172 Scan-rescan Repeatability and Cross-scanner Comparability of DTI Metrics in Healthy Subjects in the SPRINT-MS Multicenter Trial Magnetic Resonance Imaging. 11, 2018 | Pubmed ID: 30048675 Prospects of Siponimod in Secondary Progressive Multiple Sclerosis Therapeutic Advances in Neurological Disorders. 2018 | Pubmed ID: 30038666 Technical Note: Retrospective Reduction in Systematic Differences Across Scanner Changes by Accounting for Noise Floor Effects in Diffusion Tensor Imaging Medical Physics. Jul, 2018 | Pubmed ID: 29998491 Patient-Reported Disease-Modifying Therapy Adherence in the Clinic: A Reliable Metric? Multiple Sclerosis Journal - Experimental, Translational and Clinical. Apr-Jun, 2018 | Pubmed ID: 29854415 Rare Side Effects of Alemtuzumab Remind Us of the Need for Postmarketing Surveillance Neurology. May, 2018 | Pubmed ID: 29602911 Siponimod Versus Placebo in Secondary Progressive Multiple Sclerosis (EXPAND): a Double-blind, Randomised, Phase 3 Study Lancet (London, England). 03, 2018 | Pubmed ID: 29576505 Corrigendum to 'Effects of Delayed-release Dimethyl Fumarate (DMF) on Health-related Quality of Life in Patients With Relapsing-remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies: [Clinical Therapeutics 36 (2014) 1958-1971] Clinical Therapeutics. 05, 2018 | Pubmed ID: 29523369 A Survey of Dietary Characteristics in a Large Population of People with Multiple Sclerosis Multiple Sclerosis and Related Disorders. May, 2018 | Pubmed ID: 29510324 Tissue Markers for Acute Multiple Sclerosis Treatment Response-A Step Toward Personalized Medicine JAMA Neurology. Apr, 2018 | Pubmed ID: 29404560 Treatment Satisfaction and Bothersome Bladder, Bowel, Sexual Symptoms in Multiple Sclerosis Multiple Sclerosis and Related Disorders. Feb, 2018 | Pubmed ID: 29275057 Pilot Trial of Intravenous Autologous Culture-expanded Mesenchymal Stem Cell Transplantation in Multiple Sclerosis Multiple Sclerosis (Houndmills, Basingstoke, England). 04, 2018 | Pubmed ID: 28381130 Landscape of MS Patient Cohorts and Registries: Recommendations for Maximizing Impact Multiple Sclerosis (Houndmills, Basingstoke, England). 04, 2018 | Pubmed ID: 28279128 Perspectives on Marijuana Use and Effectiveness: A Survey of NARCOMS Participants Neurology. Clinical Practice. Aug, 2017 | Pubmed ID: 29185555 Advancing Trial Design in Progressive Multiple Sclerosis Multiple Sclerosis (Houndmills, Basingstoke, England). Oct, 2017 | Pubmed ID: 29041871 Comparative Efficacy and Discontinuation of Dimethyl Fumarate and Fingolimod in Clinical Practice at 24-month Follow-up Multiple Sclerosis Journal - Experimental, Translational and Clinical. Jul-Sep, 2017 | Pubmed ID: 28890796 T1-/T2-weighted Ratio Differs in Demyelinated Cortex in Multiple Sclerosis Annals of Neurology. Oct, 2017 | Pubmed ID: 28833377 DNA Methylation in Demyelinated Multiple Sclerosis Hippocampus Scientific Reports. 08, 2017 | Pubmed ID: 28821749 Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM Neurology and Therapy. Dec, 2017 | Pubmed ID: 28770420 Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM Clinical Therapeutics. Aug, 2017 | Pubmed ID: 28751099 Autologous Hematopoietic Stem Cell Transplantation for MS: Safer Than Previously Thought Neurology. 05, 2017 | Pubmed ID: 28455384 Comparative Effectiveness of Delayed-release Dimethyl Fumarate Versus Glatiramer Acetate in Multiple Sclerosis Patients: Results of a Matching-adjusted Indirect Comparison Journal of Comparative Effectiveness Research. Jun, 2017 | Pubmed ID: 28350241 High Hypothetical Interest in Physician-assisted Death in Multiple Sclerosis Neurology. Apr, 2017 | Pubmed ID: 28298551 Evidence of Activation of the Nrf2 Pathway in Multiple Sclerosis Patients Treated with Delayed-release Dimethyl Fumarate in the Phase 3 DEFINE and CONFIRM Studies Multiple Sclerosis (Houndmills, Basingstoke, England). Dec, 2017 | Pubmed ID: 28156185 Progressive Multiple Sclerosis: Prospects for Disease Therapy, Repair, and Restoration of Function Lancet (London, England). 04, 2017 | Pubmed ID: 27889191 Comparative Effectiveness Using a Matching-adjusted Indirect Comparison Between Delayed-release Dimethyl Fumarate and Fingolimod for the Treatment of Multiple Sclerosis Current Medical Research and Opinion. 02, 2017 | Pubmed ID: 27733070 Inadequate Outcome Measures Are the Biggest Impediment to Successful Clinical Trials in Progressive MS - NO Multiple Sclerosis (Houndmills, Basingstoke, England). 04, 2017 | Pubmed ID: 27729555 Imaging As an Outcome Measure in Multiple Sclerosis Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics. 01, 2017 | Pubmed ID: 27699722 Measuring Brain Tissue Integrity During 4 Years Using Diffusion Tensor Imaging AJNR. American Journal of Neuroradiology. Jan, 2017 | Pubmed ID: 27659189 Quantitative Quality Assurance in a Multicenter HARDI Clinical Trial at 3T Magnetic Resonance Imaging. Jan, 2017 | Pubmed ID: 27587227 Long-term Effects of Delayed-release Dimethyl Fumarate in Multiple Sclerosis: Interim Analysis of ENDORSE, a Randomized Extension Study Multiple Sclerosis (Houndmills, Basingstoke, England). Feb, 2017 | Pubmed ID: 27207449 Long-term Registries: Answering Tough Questions with Big Data? Neurology. Clinical Practice. Apr, 2016 | Pubmed ID: 29377024 Comparative Efficacy and Discontinuation of Dimethyl Fumarate and Fingolimod in Clinical Practice at 12-month Follow-up Multiple Sclerosis and Related Disorders. Nov, 2016 | Pubmed ID: 27919497 Examining the Joint Effect of Disability, Health Behaviors, and Comorbidity on Mortality in MS Neurology. Clinical Practice. Oct, 2016 | Pubmed ID: 27847682 Design, Rationale, and Baseline Characteristics of the Randomized Double-blind Phase II Clinical Trial of Ibudilast in Progressive Multiple Sclerosis Contemporary Clinical Trials. 09, 2016 | Pubmed ID: 27521810 Characterizing Absolute Lymphocyte Count Profiles in Dimethyl Fumarate-treated Patients with MS: Patient Management Considerations Neurology. Clinical Practice. Jun, 2016 | Pubmed ID: 27347439 Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis International Journal of MS Care. May-Jun, 2016 | Pubmed ID: 27252601 JC Polyomavirus Abundance and Distribution in Progressive Multifocal Leukoencephalopathy (PML) Brain Tissue Implicates Myelin Sheath in Intracerebral Dissemination of Infection PloS One. 2016 | Pubmed ID: 27191595 Relapses in Multiple Sclerosis: Relationship to Disability Multiple Sclerosis and Related Disorders. Mar, 2016 | Pubmed ID: 27063617 Erratum To: Reassessing the Risk of Natalizumab-associated PML Journal of Neurovirology. 08, 2016 | Pubmed ID: 27026534 Relationship Between Symptom Change, Relapse Activity and Disability Progression in Multiple Sclerosis Journal of the Neurological Sciences. Mar, 2016 | Pubmed ID: 26944131 Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies Neurology and Therapy. Jun, 2016 | Pubmed ID: 26932146 Reassessing the Risk of Natalizumab-associated PML Journal of Neurovirology. 08, 2016 | Pubmed ID: 26843383 Refining Diagnosis of Multiple Sclerosis with Revised MRI Criteria The Lancet. Neurology. Mar, 2016 | Pubmed ID: 26822747 Correlating Function and Imaging Measures of the Medial Longitudinal Fasciculus PloS One. 2016 | Pubmed ID: 26800522 No Association of Chronic Cerebrospinal Venous Insufficiency with Multiple Sclerosis The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. Jan, 2016 | Pubmed ID: 26194114 Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience Neurology and Therapy. Dec, 2015 | Pubmed ID: 26662361 Prevalence of Multiple Sclerosis Symptoms Across Lifespan: Data from the NARCOMS Registry Neurodegenerative Disease Management. 2015 | Pubmed ID: 26611264 Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies Clinical Therapeutics. Nov, 2015 | Pubmed ID: 26526385 Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study Neurology and Therapy. Dec, 2015 | Pubmed ID: 26525536 Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate International Journal of MS Care. Sep-Oct, 2015 | Pubmed ID: 26472945 Progressive MS: from Pathophysiology to Drug Discovery Multiple Sclerosis (Houndmills, Basingstoke, England). Oct, 2015 | Pubmed ID: 26362902 The Future of Research in Multiple Sclerosis JAMA Neurology. Aug, 2015 | Pubmed ID: 26053218 Chronic Cerebrospinal Venous Insufficiency: Pitfalls and Perils of Sonographic Assessment Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine. Jun, 2015 | Pubmed ID: 26014330 Risk Tolerance to MS Therapies: Survey Results from the NARCOMS Registry Multiple Sclerosis and Related Disorders. May, 2015 | Pubmed ID: 26008941 Disability Progression in Relapsing MS is More Than Just Lesions: The Lesson of Fingolimod Multiple Sclerosis (Houndmills, Basingstoke, England). Jun, 2015 | Pubmed ID: 25948627 Progressive Multiple Sclerosis Current Opinion in Neurology. Jun, 2015 | Pubmed ID: 25887766 Comment: A Better Measuring Stick for Walking in Multiple Sclerosis Neurology. May, 2015 | Pubmed ID: 25878181 Clinical Trials in Progressive Multiple Sclerosis: Lessons Learned and Future Perspectives The Lancet. Neurology. Feb, 2015 | Pubmed ID: 25772899 Efficacy of Delayed-release Dimethyl Fumarate in Relapsing-remitting Multiple Sclerosis: Integrated Analysis of the Phase 3 Trials Annals of Clinical and Translational Neurology. Feb, 2015 | Pubmed ID: 25750916 Effects of Delayed-release Dimethyl Fumarate on MRI Measures in the Phase 3 CONFIRM Study Neurology. Mar, 2015 | Pubmed ID: 25681448 Factors Associated with Clinically Significant Increased Walking Time in Multiple Sclerosis: Results of a Survival Analysis of Short-term Follow-up Data from a Clinical Database Multiple Sclerosis (Houndmills, Basingstoke, England). Apr, 2015 | Pubmed ID: 25112816 Efficacy and Safety of Delayed-release Dimethyl Fumarate in Patients Newly Diagnosed with Relapsing-remitting Multiple Sclerosis (RRMS) Multiple Sclerosis (Houndmills, Basingstoke, England). Jan, 2015 | Pubmed ID: 24990854 Observations on the Brain Vasculature in Multiple Sclerosis: A Historical Perspective Multiple Sclerosis and Related Disorders. Mar, 2014 | Pubmed ID: 25878003 Identifying the Start of Multiple Sclerosis Injury: a Serial DTI Study Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging. Nov-Dec, 2014 | Pubmed ID: 25370339 Effects of Delayed-release Dimethyl Fumarate (DMF) on Health-related Quality of Life in Patients with Relapsing-remitting Multiple Sclerosis: an Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies Clinical Therapeutics. 12, 2014 | Pubmed ID: 25315404 Biomarkers for MS: Unpuzzling the Progressive Multiple Sclerosis Puzzle Neurology. Oct, 2014 | Pubmed ID: 25253742 Risk Stratification and Mitigation Multiple Sclerosis Multiple Sclerosis and Related Disorders. Sep, 2014 | Pubmed ID: 25221744 Defining the Clinical Course of Multiple Sclerosis: The 2013 Revisions Neurology. May, 2014 | Pubmed ID: 24871874 MS Disease Activity in RESTORE: a Randomized 24-week Natalizumab Treatment Interruption Study Neurology. Apr, 2014 | Pubmed ID: 24682966 Injury to a Specific Neural Pathway Detected by Ultra-high-field MRI Neurology. Jan, 2014 | Pubmed ID: 24285615 BG-12 (dimethyl Fumarate): a Review of Mechanism of Action, Efficacy, and Safety Current Medical Research and Opinion. Feb, 2014 | Pubmed ID: 24131282 Is Neuromyelitis Optica with Advanced Age of Onset a Paraneoplastic Disorder? The International Journal of Neuroscience. Jul, 2014 | Pubmed ID: 24111490 Dimethyl Fumarate for Relapsing MS Neurology. Clinical Practice. Jun, 2013 | Pubmed ID: 29473631 Treatment Discontinuation and Disease Progression with Injectable Disease-modifying Therapies: Findings from the North American Research Committee on Multiple Sclerosis Database International Journal of MS Care. 2013 | Pubmed ID: 24453783 Hydration Status Substantially Affects Chronic Cerebrospinal Venous Insufficiency Assessments Neurology. Clinical Practice. Oct, 2013 | Pubmed ID: 24175155 Multiple Sclerosis Treatment: Risk Mitigation Continuum (Minneapolis, Minn.). Aug, 2013 | Pubmed ID: 23917104 Hippocampal Demyelination and Memory Dysfunction Are Associated with Increased Levels of the Neuronal MicroRNA MiR-124 and Reduced AMPA Receptors Annals of Neurology. May, 2013 | Pubmed ID: 23595422 In the Coming Year We Should Abandon Interferons and Glatiramer Acetate As First-line Therapy for MS: Yes Multiple Sclerosis (Houndmills, Basingstoke, England). Jan, 2013 | Pubmed ID: 23303880 Clinically Feasible MTR is Sensitive to Cortical Demyelination in MS Neurology. Jan, 2013 | Pubmed ID: 23269598 Cortical Remyelination: a New Target for Repair Therapies in Multiple Sclerosis Annals of Neurology. Dec, 2012 | Pubmed ID: 23076662 Placebo-controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis The New England Journal of Medicine. Sep, 2012 | Pubmed ID: 22992072 A Technical Approach to Dissecting and Assessing Cadaveric Veins Pertinent to Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis Neurological Research. Oct, 2012 | Pubmed ID: 22971470 Setting a Research Agenda for Progressive Multiple Sclerosis: the International Collaborative on Progressive MS Multiple Sclerosis (Houndmills, Basingstoke, England). Nov, 2012 | Pubmed ID: 22917690 Chronic Cerebrospinal Venous Insufficiency As a Cause of Multiple Sclerosis: Controversy and Reality Current Treatment Options in Cardiovascular Medicine. Apr, 2012 | Pubmed ID: 22311713 Risk Stratification and Patient Counseling for Natalizumab in Multiple Sclerosis Neurology. Feb, 2012 | Pubmed ID: 22282644 A Validation Study of Multicenter Diffusion Tensor Imaging: Reliability of Fractional Anisotropy and Diffusivity Values AJNR. American Journal of Neuroradiology. Apr, 2012 | Pubmed ID: 22173748 Advances in the Management of PML: Focus on Natalizumab Cleveland Clinic Journal of Medicine. Nov, 2011 | Pubmed ID: 22123933 Chronic Cerebrospinal Venous Insufficiency: a Kuhnian Paradigm Shift or Another Fad? CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. Nov, 2011 | Pubmed ID: 21969409 Demyelination Causes Synaptic Alterations in Hippocampi from Multiple Sclerosis Patients Annals of Neurology. Mar, 2011 | Pubmed ID: 21446020 Advanced MRI in Multiple Sclerosis: Current Status and Future Challenges Neurologic Clinics. May, 2011 | Pubmed ID: 21439446 Web-based Self-management for Patients with Multiple Sclerosis: a Practical, Randomized Trial Telemedicine Journal and E-health : the Official Journal of the American Telemedicine Association. Jan-Feb, 2011 | Pubmed ID: 21214498 Measuring Myelin Repair and Axonal Loss with Diffusion Tensor Imaging AJNR. American Journal of Neuroradiology. Jan, 2011 | Pubmed ID: 20947644 Diagnosing Multiple Sclerosis at a Later Age: More Than Just Progressive Myelopathy Multiple Sclerosis (Houndmills, Basingstoke, England). Nov, 2010 | Pubmed ID: 20670982 Imaging Correlates of Leukocyte Accumulation and CXCR4/CXCL12 in Multiple Sclerosis Archives of Neurology. Jan, 2009 | Pubmed ID: 19139298 Picturing Multiple Sclerosis: Conventional and Diffusion Tensor Imaging Seminars in Neurology. Sep, 2008 | Pubmed ID: 18843574 A Preliminary Validation Study of Diffusion Tensor Imaging As a Measure of Functional Brain Injury Archives of Neurology. Sep, 2008 | Pubmed ID: 18779420 Multiple Sclerosis: Chemokine Receptor Expression on Circulating Lymphocytes in Correlation with Radiographic Measures of Tissue Injury Multiple Sclerosis (Houndmills, Basingstoke, England). Sep, 2008 | Pubmed ID: 18701575 Neurogenesis in the Chronic Lesions of Multiple Sclerosis Brain : a Journal of Neurology. Sep, 2008 | Pubmed ID: 18669500 Optimal Reference Population for the Multiple Sclerosis Functional Composite Multiple Sclerosis (Houndmills, Basingstoke, England). Aug, 2007 | Pubmed ID: 17468446 Treatment of Susac Syndrome with Gamma Globulin and Corticosteroids Journal of the Neurological Sciences. Dec, 2006 | Pubmed ID: 17052732 Multiple Sclerosis: Treating Symptoms, and Other General Medical Issues Cleveland Clinic Journal of Medicine. Feb, 2006 | Pubmed ID: 16478042 Multiple Sclerosis: Advances in Understanding, Diagnosing, and Treating the Underlying Disease Cleveland Clinic Journal of Medicine. Jan, 2006 | Pubmed ID: 16444920 Mitochondrial Dysfunction As a Cause of Axonal Degeneration in Multiple Sclerosis Patients Annals of Neurology. Mar, 2006 | Pubmed ID: 16392116 Modulating CCR2 and CCL2 at the Blood-brain Barrier: Relevance for Multiple Sclerosis Pathogenesis Brain : a Journal of Neurology. Jan, 2006 | Pubmed ID: 16230319 Should Patients with Relapsing Multiple Sclerosis Be Given a Higher Dose and Frequency of Interferon-beta1a? Nature Clinical Practice. Neurology. Nov, 2005 | Pubmed ID: 16932486 Brain Atrophy and Magnetization Transfer Ratio Following Methylprednisolone in Multiple Sclerosis: Short-term Changes and Long-term Implications Multiple Sclerosis (Houndmills, Basingstoke, England). Apr, 2005 | Pubmed ID: 15794385 New Directions in MS Therapeutics: Vehicles of Hope Trends in Immunology. Dec, 2004 | Pubmed ID: 15530830 Multiple Sclerosis: Disease Markers Accelerate Progress Lancet Neurology. Jan, 2004 | Pubmed ID: 14693099 Comprehensive Autopsy Program for Individuals with Multiple Sclerosis Ranjan Dutta*1, Kedar R. Mahajan*1,3, Kunio Nakamura*3, Daniel Ontaneda*2, Jacqueline Chen1, Christina Volsko1, Jessica Dudman1, Emilie Christie1, Jordon Dunham1, Robert J. Fox3, Bruce D. Trapp1 1Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, 2Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, 3Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland Clinic JoVE 59511 Neurociência
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis Ranjan Dutta*1, Kedar R. Mahajan*1,3, Kunio Nakamura*3, Daniel Ontaneda*2, Jacqueline Chen1, Christina Volsko1, Jessica Dudman1, Emilie Christie1, Jordon Dunham1, Robert J. Fox3, Bruce D. Trapp1 1Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, 2Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, 3Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland Clinic JoVE 59511 Neurociência